» Articles » PMID: 11517930

Activation of Progelatinase A by Mammalian Legumain, a Recently Discovered Cysteine Proteinase

Overview
Journal Biol Chem
Specialty Biochemistry
Date 2001 Aug 24
PMID 11517930
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

The activation of progelatinase A to gelatinase A requires cleavage of an asparaginyl bond to form the N-terminus of the mature enzyme. We have asked whether the activation can be mediated by legumain, the recently discovered lysosomal cysteine proteinase that is specific for hydrolysis of asparaginyl bonds. Addition of purified legumain to the concentrated conditioned medium from HT1080 cell culture that contained both progelatinases A and B caused the conversion of the 72 kDa progelatinase A to the 62 kDa form. The progelatinase B in the medium was unaffected. Incubation of recombinant progelatinase A with legumain resulted in an almost instantaneous activation as judged by the fluorometric assay with a specific gelatinase A substrate, Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2. Legumain also activated progelatinase A when it was in complex with TIMP-2. Zymographic analysis and N-terminal sequencing revealed that legumain cleaved the 72 kDa progelatinase A at the bonds between Asn109-Tyr110 or Asn111-Phe112 to produce the 62 kDa mature enzyme, and that further cleavage at Asn430 also occurred to generate a 36 kDa active form. More 62 kDa gelatinase A was detected in cultures of C13 cells that over-expressed legumain than in those of the control HEK293 cells. We conclude that legumain is clearly capable of processing progelatinase A to the active enzyme in vitro and in cultured cells.

Citing Articles

Serum legumain is a potential biomarker for community-acquired pneumonia: a prospective cohort study.

Meng X, Ma K, Qu K, Cheng Z, Fu L, Qu Y Int J Med Sci. 2025; 22(5):1072-1080.

PMID: 40027188 PMC: 11866532. DOI: 10.7150/ijms.106118.


Non-Canonical, Extralysosomal Activities of Lysosomal Peptidases in Physiological and Pathological Conditions: New Clinical Opportunities for Cancer Therapy.

Conesa-Bakkali R, Morillo-Huesca M, Martinez-Fabregas J Cells. 2025; 14(2).

PMID: 39851495 PMC: 11763575. DOI: 10.3390/cells14020068.


Legumain in cardiovascular diseases.

Zhou L, Wu J, Wei Z, Zheng Y Exp Biol Med (Maywood). 2024; 249:10121.

PMID: 39104790 PMC: 11298360. DOI: 10.3389/ebm.2024.10121.


Protein S-Nitrosylation: A Chemical Modification with Ubiquitous Biological Activities.

Aboalroub A, Al Azzam K Protein J. 2024; 43(4):639-655.

PMID: 39068633 DOI: 10.1007/s10930-024-10223-y.


Association between high plasma levels of legumain and cardiovascular events in patients undergoing coronary angiography.

Momiyama Y, Kishimoto Y, Saita E, Ohmori R, Kondo K Heart Vessels. 2024; 39(10):909-915.

PMID: 38289388 DOI: 10.1007/s00380-024-02373-x.